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Do I really need to have that test?

Understanding risk and making medical decisions in the age of TMI.
Gene Elizabeth Harkless, DNSc, APRN
Associate Professor of Nursing

Introduction

E

ven in the age of Too Much Information,
the truth is that in health care we have less hard
data for treatment effectiveness than most people
believe. Often, predicting a serious problem with precision is beyond our science. So, when a clinician tests
for a diagnosis or recommends a treatment, what may
be lurking behind that decision? Is it evidence-based
reasoning? Or, could it be market-based pressures, ingrained ritual, or simply clinical ignorance?
Are you, the consumer, entering the health care visit
with fear or hope fueled by the barrage of media proclaiming health threats and new, powerful treatments?
How do you decide what to do?
Using skills and strategies based in health literacy
may help bring sanity to this confusing onslaught of
information. The clinician and the consumer both need
a healthy dose of skepticism, the ability to discriminate among information sources, and mastery of a few
simple numerical concepts. Even for healthy young
people, the use of these skills and strategies can help
cut through the hype and provide evidence to consider
when deciding to seek care, participate in screening
tests, or consider using a medication.
But, is our health care system set up to support and
encourage expanded health literacy? What may be the
drawbacks of promoting a more activated, informed
consumer? And, lastly, as we become better at discriminating overload information and hype from the essential and important particulars in health care information, will we achieve health outcomes that matter?

Is treatment always needed?

T

hink about why you go to the “doctor.” (Because I
am a family nurse practitioner, I choose to use the
more inclusive term “clinician” in place of “doctor” as
clinician includes many different primary care providers
including nurse practitioners, nurse-midwives, physician
assistants, and physicians.) Perhaps you were first taken
to the clinician for an acute care visit because an earache
complicated an otherwise mild illness. Your parents believed any ear infection to be dangerous, requiring immediate treatment with antibiotics to avoid short-term
severe illness and long-term hearing complications.

Today, we know that is not so. Ear infections in young
healthy children over age two with mild to moderate
symptoms are best managed with a watch-and-wait
approach that delays any use of antibiotics for 48 to 72
hours.1 By this time most children will not need antibiotics. At 24 hours, 61% of children have decreased symptoms whether they receive a placebo or an antibiotic.
To understand this better, a concept called “number
needed to treat” helps us figure out how much added
benefit a drug or other treatment provides beyond what
would improve if you just waited for time to pass.
For children with ear infections, because at least twothirds (or maybe as high as 90%) improve without antibiotics, many children would have to be treated with
antibiotics to help the few who may benefit. That the
number needed to treat for this problem is more than 7
(and may be as high as 20), means you have to treat at
least 7 children who would get better on their own to
improve the outcome of just 1 child, who would need an
antibiotic to improve.
So, the outcome for just about all of the children
given early antibiotics was not improved by the giving of antibiotics, because they were going to get better
without any treatment. And, it means that each child
not benefiting from an antibiotic was exposed to the
risk of an allergic reaction, and that parents and/or the
health care system incurred a significant amount of cost
involved in obtaining that antibiotic.
Our science does not yet help us identify which 1 of
the 7 to 20 children will benefit from early antibiotic
treatment and for this we may need better diagnostic
discriminators. Perhaps this information is hidden in
our genome (stay tuned for those developments). But for
now, medicine has recognized the unintended consequences of over-treatment, including problems such as
antibiotic resistance and increased cost of care.
Acute ear infection is just one condition, among
many common ailments, including acute low back pain
that, based on current evidence, indicate overly aggressive use of medical treatment. Is this also the case for
disease screening?

TMI: Decision Making in the Age of Information Overload

New evidence, major changes in cancer screening

E

ven beyond our inability to say precisely what treatments are truly effective and who will benefit from
these treatments, we have great imprecision in our diagnostic and screening processes. If you are female, you
are well aware of how many “health screening” actions
you are expected to participate in, including those for
breast and cervical cancer. If you are male, you probably visit clinicians for care far less often. Data from as
recently as 2006 showed that young men between the
ages of 20–29 years of age had less than one quarter the
rate of visits for preventive care compared with young
women. Female visits for Pap smears account for half
of this difference.2 For these reasons, the examples here
will focus on cancer screening for young women.
For decades, young women have been taught that
breast cancer is deadly and must be diagnosed early to
save lives. Women of all ages were expected to conduct
monthly breast self-exams. Boys, not to be excluded
from monthly search-and-find missions, were taught
testicular self-exam, which is another unsupported
intervention.2, 3 During the “annual physical exam (another clinical service that has been found lacking in its
effectiveness)” 4-6 young women from puberty onward
were exhorted to continue breast self-exams and the
skill was reinforced each visit. Finally, in 2009, the U.S
Preventive Services Task Force (USPSTF), an independent panel of experts, systematically reviewed breast
cancer screening research. Their analysis and recommendations exploded our old rituals of care .7
Relying on high-quality, large clinical trials that
found breast self-exams resulted in high rates of referral
for suspicious masses with no evidence of lives saved,
the USPSTF graded the evidence for breast self-exams
as “D.”7 A “D” grade means that there is moderate or
high certainty that the service has no net benefit or that
the harms outweigh the benefits and that the practice
should be discouraged. Now, in contrast to preceding
decades of clinical and social marketing messages powerfully reinforcing the importance for breast self-exam
(and, in more than a few cases, women feeling guilty for
not practicing this “health-saving” practice), breast selfexam is now out of favor.
Clearly, medicine is learning more and more that
“the extent to which beliefs are based on evidence are
very much less than believers suppose.”8 Similarly for
the clinical breast exam, the “C” grade assigned by the
USPSTF means that the net benefit is small and that the
service should not be routinely provided, especially in
women under age 40.7
Young women are also encouraged to be screened
for cervical cancer. Wrongly, in my opinion. Too many

clinicians continue to require cervical cancer screening
as a mandatory prerequisite to prescribing contraception. It makes no sense to link pregnancy prevention to
participation in a cancer prevention program. But over
many decades, women have been held hostage to this
ridiculous linkage—no Pap test, no contraceptives.
The Pap test takes cells from the transformation zone
of the cervix, which is the junction where cervical dysplasias (abnormal cells) arise. Out of those abnormal
cells, rarely, and more often if HPV types 16 and 18
are present, cervical cancer may develop. (Note: the
HPV vaccine is safe and effective at protecting against
these types.) Putting this into perspective, each year
2 to 3 million Pap tests are interpreted as abnormal.
Out of those, less than one half of one percent (0.5%),
or 100,000 to 150,000, are high-grade dysplasia and of
those high-grade lesions, there is a less than a 15% rate
of progression to invasive cervical cancer over about 5
to 15 years.9 Over 70% (at least 10,500 out of the 15,000)
of those cases are related to HPV type 16 and 18.10
With our current understanding of the natural progression and resolution of low-grade cell changes of the
cervix, it is now recommended that young women not
be tested for cervical cancer before the age of 21. After
age 21, a less than annual testing schedule, often every
three years, is recommended for most women.9 This less
aggressive approach prevents unnecessary interventions
for mild abnormalities that will revert back to normal
on their own while preserving the important benefits
of cancer screening. This new, less aggressive approach
earned an “A” grade by the USPSTF.9
But, in spite of the best evidence, when clinicians
were surveyed recently, less than 25% followed the new
recommendations, and most chose screening options
that overused services.11
One other USPSTF “A” grade screening recommendation is testing for chlamydia infection in sexually active women age 24 or younger. Chlamydia trachomatis
infects three million new people each year in the U.S.
and it is a major cause of infertility, pelvic inflammatory
disease, and tubal (ectopic) pregnancy in women. Most
infected women have no symptoms. Therefore, screening using a nucleic amplification test has the potential
to uncover hidden infections. Treatment can then be
given to those who test positive. This will minimize the
spread of the infection and decrease the risk of complications, improving the overall health of this young adult
population. However, even though chlamydia screening
received an “A” rating and the test is very good at identifying those infected, the test is not perfect. How so?
The evidence is clear that nucleic amplification tests
have test sensitivities of up to 97%.12 This means that
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if 30 out of every 1,000 sexually active young women
between the ages of 15 and 24 are expected to have chlamydia, the nucleic amplification test will correctly identify 29 of these women (30 x .97 = 29). One woman will
be told she does not have chlamydia when she actually
has the infection. That is called a false negative and neither false negatives nor false positives are medical errors
but simply the nature of imperfect tests.
The specificities of the nucleic amplification tests are
also high at about 99%.12 Of the 970 young women who
are tested for chlamydia but are not expected to have the
infection, the test will correctly identify 99% of those,
or 960 women. But, 10 women may be told they have
chlamydia when, in fact, they do not have the infection.
Again, these false positives are because the test is not
perfect, not because of medical error. And, very importantly, samples obtained by urine tests are as reliable
as cervical swabs.12 Hence, screening for this sexually
transmitted disease can be done easily, although not as
perfectly as many would like to believe.

Conclusion

A

fter working through the evidence that clarifies the
reasoning behind the treatment and screening of
a few conditions, I hope I’ve imparted a healthy skepticism about current practices. And, I’ve underscored
what abilities are required to discriminate evidence
from values and beliefs. I want to leave you with a few
high-quality, evidence-based resources that promote
health literacy.
Becoming an informed, activated health care consumer is now up to you. For future conversations, the
following questions remain: What may be the drawbacks of promoting a more activated, informed consumer? And, lastly, as we become better at discriminating overload information and hype from the essential
and important particulars in health care information,
will we achieve health outcomes that matter?
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